Tunger, A.; Kießler, M.; Wehner, R.; Temme, A.; Meier, F.; Bachmann, M.; Schmitz, M.
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines 2018, 6, 26.
https://doi.org/10.3390/biomedicines6010026
AMA Style
Tunger A, Kießler M, Wehner R, Temme A, Meier F, Bachmann M, Schmitz M.
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines. 2018; 6(1):26.
https://doi.org/10.3390/biomedicines6010026
Chicago/Turabian Style
Tunger, Antje, Maximilian Kießler, Rebekka Wehner, Achim Temme, Friedegund Meier, Michael Bachmann, and Marc Schmitz.
2018. "Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment" Biomedicines 6, no. 1: 26.
https://doi.org/10.3390/biomedicines6010026
APA Style
Tunger, A., Kießler, M., Wehner, R., Temme, A., Meier, F., Bachmann, M., & Schmitz, M.
(2018). Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines, 6(1), 26.
https://doi.org/10.3390/biomedicines6010026